The Haemanthus Mystery: Beyond the Theranos Ghost

Billy Evans’ venture, Haemanthus, is fighting an uphill battle to distance itself from the toxic legacy of Theranos. Despite public assertions that the firm is not a reincarnation of the infamous fraud, investigative scrutiny into its leadership—specifically co-founders Lauren Friedman Stat, a Palantir board member and longtime associate of Elizabeth Holmes, and her husband, Dr. David Stat—has ignited significant skepticism. The startup, whose name translates from Greek to “blood flower,” is reportedly developing laser-based diagnostic technology for biological samples, yet the extent of Holmes’ involvement remains shrouded in ambiguity.

The narrative surrounding Haemanthus is complicated by conflicting accounts: while the company publicly denies being 'Theranos 2.0,' sources close to Evans have allegedly used that exact phrasing to describe the project.

The recent cinematic spotlight provided by Nathan Fielder and Lance Oppenheim’s film, You Can See Everything, has only intensified public interest in the partnership between Evans and the incarcerated Holmes. With reports suggesting the venture may have been conceived as a morale-boosting project for Holmes ahead of her transition to the Austin Transitional Center in 2026, the industry is left wondering if this “blood flower” can truly bloom in a market still reeling from the Theranos collapse.

Ossium Health: Pioneering the Future of Bone Marrow Transplants

While some startups struggle with reputation, others are revolutionizing medicine. Ossium Health, founded in 2016 by Kevin Caldwell and Erik Woods, has successfully challenged the medical consensus that bone marrow could not be cryopreserved. After proving that frozen marrow is as effective—if not superior—to fresh donations, the company is scaling for commercialization. With revenue projected to hit $120 million in 2026, Ossium is positioning itself to become a dominant force in treating blood cancers, sickle cell anemia, and immune disorders.

The Rising Cost of Care and Emerging Health Risks

As the healthcare landscape shifts, consumers are facing significant financial strain. Employer-sponsored healthcare costs are projected to climb by 9.5% in 2027, while Affordable Care Act (ACA) benchmark plans have seen a 13% spike in premiums, following a 26% increase the previous year. These rising costs, compounded by the expiration of enhanced tax credits, are forcing many to reconsider their coverage.

Key Developments in Healthcare

  • Political Engagement: An unprecedented 125 medical professionals appeared on ballots during the recent midterms.
  • AI Risks: A tragic case involving a young woman with epilepsy highlights the dangers of patients using AI tools like ChatGPT to bypass professional medical guidance.
  • Regulatory Failures: Growing concerns persist regarding insurers allegedly violating consumer protection laws by denying emergency medical claims.
  • Peptide Dangers: The 2025 death of actor Richard Norton has been linked to the use of peptides like ipamorelin, underscoring the severe risks associated with unregulated fitness supplements.